ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Active:	Yes
Cancer Type:	Hematopoietic Malignancies Lymphoma Non-Hodgkin Lymphoma Unknown Primary	NCT ID:	NCT05653271
Trial Phases:	Phase I	Protocol IDs:	ACE1831-001 (primary) NCI-2023-03335
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Acepodia Biotech, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT05653271

Summary

ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy
donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies.

The ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to
evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and efficacy of
ACE1831 in patients with CD20-expressing Non-Hodgkin lymphoma.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.